# Case Report: Evolution and targeted therapy of an EGFR-mutant large-cell neuroendocrine carcinoma

## TL;DR

A patient with a rare lung cancer type and an EGFR mutation showed long-term response to targeted therapy and chemotherapy, emphasizing the need for ongoing molecular testing.

## Contribution

This case report demonstrates the dynamic evolution of EGFR-mutant LCNEC and the effectiveness of adaptive targeted therapy and chemotherapy.

## Key findings

- The patient had 20 months of progression-free survival with osimertinib as first-line therapy.
- Switching to etoposide and cisplatin with radiotherapy provided 7 months of disease control.
- Third-line therapy with paclitaxel, carboplatin, and bevacizumab extended progression-free survival by 21 months.

## Abstract

We report the case of a 47-year-old female non-smoker diagnosed with stage IV large-cell neuroendocrine carcinoma (LCNEC) of the lung harboring an EGFR exon 21 L858R mutation. The patient exhibited a sustained response to first-line osimertinib, with a progression-free survival of 20 months, followed by transformation to small-cell lung cancer (SCLC) confirmed via histopathological reassessment. Second-line treatment with etoposide and cisplatin combined with radiotherapy resulted in an additional 7 months of disease control. Subsequent progression was accompanied by features suggestive of adenocarcinoma, supported by elevated carcinoembryonic antigen levels, stable neuron-specific enolase, and circulating tumor DNA profiling. Third-line chemotherapy with paclitaxel, carboplatin, and bevacizumab, followed by maintenance therapy with aumolertinib and anlotinib, extended progression-free survival by 21 months. Overall survival reached 48 months. This case highlights the critical importance of repeated molecular profiling and histologic reevaluation in guiding therapeutic decisions for EGFR-mutant LCNEC undergoing phenotypic evolution.